<DOC>
	<DOCNO>NCT01303497</DOCNO>
	<brief_summary>Efficacity Paclitaxel association Bevacizumab treatment angiosarcoma</brief_summary>
	<brief_title>Efficacity Weekly Paclitaxel Association Not With Bevacizumab Metastatic Locally Advanced Angiosarcomas</brief_title>
	<detailed_description>Randomization stratify : - angiosarcoma irradiated region : yes / - visceral angiosarcoma : yes / All patient receive maximum 6 cycle weekly Paclitaxel ( Arm A B ) association Bevacizumab ( ArmB ) . 1 cycle = 28 day Treatment Bevacizumab continue beyond 6th cycle , disease progression unacceptable toxicity Arm A B : Day 1 , D8 D15 Paclitaxel : 90 mg/m² , IV weekly premedication Arm B : Day 1 D15 Bevacizumab : 10 mg/kg , Bevacizumab : 15 mg/kg/3 week disease progression unacceptable toxicity</detailed_description>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Angiosarcoma histologically proven Metastatic locally advance accessible surgery treatment Measurable tumor least 1 measurable lesion , accord RECIST For angiosarcoma irradiated region , absence clinical argument progression tumor prior treat radiation At least 28 day since previous treatment ( systemic major surgery ) Performance Status ( ECOG ) ≤ 1 Man woman &gt; = 18 year Polynuclear neutrophils &gt; 1500/mm3 , platelet &gt; 100 000/ mm3 , Hemoglobin &gt; 9.0 g/dl Total bilirubin ≤ 1.5 x USL , AST ALT ≤ 2.5 x USL ( ≤ 5 hepatic metastasis ) Serum creatinin ≤ 1.5 x USL clearance calculate &gt; 50 ml/mn ( Cockcroft formula ) Absence hematuria dipstick Proteinuria dipstick &lt; 2+ , &gt; 2 , 24 hour proteinuria must &lt; 1g Albumin &gt; 35 g/l lymphocyte &gt; 700/mm3 attest life expectancy &gt; 3 month Normal cardiac function : LVEF ≥ 50 % Normal coagulation test : INR ≤ 1.5 TCA ≤ 1.5 x USL within 7 day inclusion Systolic BP ≤ 150 mmHg diastolic BP ≤ 100 mmHg Negative pregnancy test woman reproductive potential ( within 7 day treatment start ) Effective contraceptive method male female ( applicable ) period treatment 6 month last administration Bevacizumab Adequate central veinous access Patient cover government health insurance Informed consent form sign patient Patients receive 2 regimen chemotherapy whatever indication Kaposi 's sarcoma , hemangioendothelioma , hemangiopericytoma ( Malignant solitary fibrous tumor ) Surgery ( except diagnostic biopsy ) radiotherapy within past 4 week inclusion , except antalgic radiotherapy Uncontrolled , active peptic ulcer , Other malignant evolutive tumor Previous thrombotic hemorrhagic disorder Clinically significant cardiovascular disease ( stroke within 6 month prior inclusion , unstable angina , heart failure , myocardial infarction , arrhythmia require treatment ) Anticoagulant treatment curative aim within 10 day begin treatment ( oral parenteral administration ) , aspirin &gt; 325 mg/day , Plavix thrombolytic ( thrombolytic preventive use permit ) antiplatelet ( dipyridamol , ticlopidine , clodiprogel , cilostazol ) Chronic treatment ( 15 day ) every AINS include aspirin &gt; 325 mg/j Currently active bacterial fungus infection ( grade &gt; 2 CTCAE v4.02 ) Known HIV1 , HIV2 , hepatitis B hepatitis C infection Presence know meningeal brain metastasis Epilepsy require use antiepileptic Previous organ transplant Peripheral stem cell transplantation within 4 month prior inclusion study Using drug affect biological response , example GCSF , within 3 week inclusion Kidney dialysis patient Clinically significant neuropathy ( grade &gt; 2 CTCAE V4.02 ) Any circumstance could jeopardise compliance proper followup trial Pregnant nursing woman . Women breastfeed least 6 month last administration Bevacizumab Constitutional acquire coagulopathy Uncontrolled hypertension ( SBP &gt; 150 mmHg DBP &gt; 100 mmHg ) Known hypersensitivity paclitaxel one excipients ( Cremophor EL , Bevacizumab component , product Chinese hamster ovary cell ( CHO ) recombinant human humanized antibody Patients unable undergo trail medical followup geographical , social psychological reason Patient refusal ambulatory care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Angiosarcoma</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>bevacizumab</keyword>
</DOC>